Back to Search Start Over

Usefulness of skin advanced glycation end products to predict coronary artery calcium score in patients with type 2 diabetes.

Authors :
Planas A
Simó-Servat O
Bañeras J
Sánchez M
García E
Ortiz ÁM
Ruiz-Meana M
Hernández C
Ferreira-González I
Simó R
Source :
Acta diabetologica [Acta Diabetol] 2021 Oct; Vol. 58 (10), pp. 1403-1412. Date of Electronic Publication: 2021 May 25.
Publication Year :
2021

Abstract

Aim: The early identification of type 2 diabetic (T2D) patients at risk of developing coronary artery disease (CAD) remains a challenge. The coronary artery calcium score (CACs) is considered the most sensitive tool for assessing CAD risk in diabetic population, and the identification of a more targeted population in which the CACs would be more cost-efficient seems warranted. The accumulation of advanced glycation end products plays an important role in the pathogenesis of cardiovascular disease (CVD) in patients with diabetes. The aim of this study was to evaluate whether the assessment of skin autofluorescence (SAF) could be useful tool to identify those diabetic patients in whom CACs assessment should be prioritized.<br />Methods: Prospective case-control study, comprising 156 subjects with T2D with no history of clinical CVD and 52 non-diabetic subjects matched by age. A value of CACs ≥ 400 Agatston Units (AU) was considered as "high CVD risk." Logistic regression analysis to predict a CACs ≥ 400 AU was performed. Sensibility and specificity were calculated using the optimal cutoff point based on ROC curve.<br />Results: T2D patients had higher value of SAF compared to controls (p = 0.011). Among subjects with diabetes, 122 presented CACs < 400 AU and 35 CACs ≥ 400 AU. SAF values were significantly higher among the group with CACs ≥ 400AU compared to patients with CACs < 400 (2.96 ± 0.86 vs. 2.59 ± 0.57; p = 0.0035). The logistic regression analysis showed that age, HDL-cholesterol and SAF values were independently related to CACs ≥ 400UA.<br />Conclusion: Our finding suggests that SAF could be useful in selecting T2D patients in whom the screening for CAD by means of CACs assessment would be more cost-effective.<br /> (© 2021. Springer-Verlag Italia S.r.l., part of Springer Nature.)

Details

Language :
English
ISSN :
1432-5233
Volume :
58
Issue :
10
Database :
MEDLINE
Journal :
Acta diabetologica
Publication Type :
Academic Journal
Accession number :
34032928
Full Text :
https://doi.org/10.1007/s00592-021-01735-5